In this Industry Viewpoint, CTA’s Elizabeth Williams speaks with Philip Arlen to discuss...
Expert Insights: EMA Reinforces Stance on Biosimilar Use for Sustainable Health Care in New Educational Video
Chloé Thépaut, MRes, Oncology Senior Analyst, GlobalData, examines the importance of the EMA’s efforts to improve patient and physician education on biosimilar medicines
Patient Recruitment Strategies for Rare Diseases – Part II: Obtaining Access to a Limited Patient Pool
Ramani A. Aiyer, Principal, Shasta BioVentures, offers a primer on patient recruitment strategies for rare disease clinical trials
Patient-Centric Clinical Trials │ How to Navigate the Clinical Trials Highway
Robert Greene, Founder and President, HungerNdThirst Foundation and Professional Patient, explains why patients should have easier access to clinical trials
Announcing ‘Patient Centricity Week’ on Clinical Trials Arena
Throughout this week, CTA will spotlight the continual rise of patient centricity
Industry Viewpoints: Investigator-Initiated Studies – A Challenge for Supply with IMPs?
Peter Orosz, Head of Clinical Supply Chain Management & Oncology, Boehringer Ingelheim, addresses the challenges of investigator-initiated clinical trials
Expert Insights: What Does the Future Hold for US Biosimilars?
Fern Barkalow, PhD, Oncology and Hematology Director, GlobalData, explores the future of biosimilars in light of the FDA’s recent move to bolster development